MDSCs have been associated with tumor progression and angiogenesis [14], and may contribute to the development of tumor resistance to anti-VEGF treatment [2].The multi-targeted nature of M402 suggests the possibility that it may confer protection against the development of resistance to VEGF-specific therapies. This evidence concerns the gene VEGFA and neoplasm.